Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 5:10 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 121–144 of 164 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: ACEi Clear all
Completed No phase listed Observational

Effects of Chronic Antihypertensive Therapy on Clinical Outcomes in Septic Shock

NCT02876341
View directory record Official record
Conditions
Atrial Fibrillation, Septic Shock
Interventions
Not listed
Lead sponsor
Rush University Medical Center
Other
Eligibility
18 Years and older
Enrollment
133 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Apr 13, 2017 · Synced Oct 21, 2026, 5:10 AM EDT
Withdrawn No phase listed Observational

The Regression of Liver Fibrosis and Risk for Hepatocellular Carcinoma (ROLFH) Study

NCT01831037
View directory record Official record
Conditions
Chronic Hepatitis C, Chronic Hepatitis B
Interventions
Regression of fibrosis, Specific risk factors related to hepatocellular carcinoma
Other
Lead sponsor
University of Arkansas
Other
Eligibility
18 Years to 70 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
2
States / cities
Little Rock, Arkansas • Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 28, 2015 · Synced Oct 21, 2026, 5:10 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Genetic Determinants of ACEI Prodrug Activation

NCT03051282
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Enalapril
Drug
Lead sponsor
University of Michigan
Other
Eligibility
18 Years to 55 Years
Enrollment
21 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2026
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Feb 18, 2026 · Synced Oct 21, 2026, 5:10 AM EDT
Completed Phase 2 Interventional Results available

Study Exploring the Effect of Crizanlizumab on Kidney Function in Patients With Chronic Kidney Disease Caused by Sickle Cell Disease

NCT04053764
View directory record Official record
Conditions
Sickle Cell Disease (SCD)
Interventions
Crizanlizuamb, Standard of Care
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
6
States / cities
Birmingham, Alabama • Chicago, Illinois • Baton Rouge, Louisiana + 3 more
Source: ClinicalTrials.gov public record
Updated Oct 9, 2024 · Synced Oct 21, 2026, 5:10 AM EDT
Completed No phase listed Observational

A Real-world Study to Compare the Effectiveness of Sacubitril/Valsartan Versus ACEi/ARB in HFrEF Patients

NCT07376265
View directory record Official record
Conditions
Heart Failure
Interventions
Not listed
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
1,249 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
East Hanover, New Jersey
Source: ClinicalTrials.gov public record
Updated Feb 4, 2026 · Synced Oct 21, 2026, 5:10 AM EDT
Recruiting Early Phase 1 Interventional

A Study to Determine the Preferred Dose of the Drug, Lisinopril, for Preventing Urinary Toxicity Following Radiotherapy for Prostate Cancer

NCT05530655
View directory record Official record
Conditions
Prostate Cancer, Radiation Toxicity, Urinary Complication
Interventions
Lisinopril Tablets
Drug
Lead sponsor
University of Rochester
Other
Eligibility
18 Years to 70 Years · Male only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Jul 23, 2026 · Synced Oct 21, 2026, 5:10 AM EDT
Completed Phase 3 Interventional Results available

Occluded Artery Trial (OAT)

NCT00004562
View directory record Official record
Conditions
Cardiovascular Diseases, Heart Diseases, Myocardial Infarction, Heart Failure, Congestive, Heart Failure
Interventions
Beta adrenergic blockers, Platelet inhibitors, PTCA and stents, ACE Inhibitors
Drug · Procedure
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older
Enrollment
2,201 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2011
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 21, 2014 · Synced Oct 21, 2026, 5:10 AM EDT
Terminated Not applicable Interventional Accepts healthy volunteers Results available

Ramipril for the Treatment of Oligospermia

NCT01856361
View directory record Official record
Conditions
Oligospermia, Teratospermia, Asthenozoospermia, Male Infertility
Interventions
Ramipril, Placebo
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years to 45 Years · Male only
Enrollment
2 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2016
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 2, 2017 · Synced Oct 21, 2026, 5:10 AM EDT
Completed No phase listed Observational

Guideline Directed Medical Therapy in Patients With Heart Failure

NCT06700213
View directory record Official record
Conditions
Heart Failure
Interventions
Not listed
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 25, 2025 · Synced Oct 21, 2026, 5:10 AM EDT
Completed No phase listed Observational

Comparative Effectiveness of Entresto (Sacubitril/Valsartan) Versus ACEi/ARB in de Novo Heart Failure Patients

NCT05963282
View directory record Official record
Conditions
de Novo Heart Failure
Interventions
Not listed
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
9,870 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
East Hanover, New Jersey
Source: ClinicalTrials.gov public record
Updated Jul 27, 2023 · Synced Oct 21, 2026, 5:10 AM EDT
Completed Not applicable Interventional Results available

Baroreflex Activation Therapy for Heart Failure

NCT02627196
View directory record Official record
Conditions
Heart Failure
Interventions
BAROSTIM NEO® System, Medical Management
Device · Drug
Lead sponsor
CVRx, Inc.
Industry
Eligibility
21 Years and older
Enrollment
1,090 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2023
U.S. locations
88
States / cities
Chandler, Arizona • Mesa, Arizona • Phoenix, Arizona + 74 more
Source: ClinicalTrials.gov public record
Updated Mar 10, 2026 · Synced Oct 21, 2026, 5:10 AM EDT
Terminated Phase 2 Interventional Results available

Evaluation of Ecallantide for Treatment of Angiotensin Converting Enzyme (ACE) Inhibitor Induced Angioedema

NCT01343823
View directory record Official record
Conditions
ACE Inhibitor Induced Angioedema
Interventions
ecallantide 60 mg, ecallantide 30 mg, ecallantide 10 mg, placebo, placebo match for 30 mg ecallantide arm, placebo match for 10 mg ecallantide arm
Drug
Lead sponsor
Shire
Industry
Eligibility
18 Years and older
Enrollment
79 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
39
States / cities
Montgomery, Alabama • Colton, California • Los Angeles, California + 33 more
Source: ClinicalTrials.gov public record
Updated Jun 11, 2021 · Synced Oct 21, 2026, 5:10 AM EDT
Completed Phase 4 Interventional Results available

Randomized Conversion of Calcineurin-Inhibitors in Renal Allograft Recipients

NCT00866879
View directory record Official record
Conditions
Renal Transplant Rejection
Interventions
Sirolimus, Demographic Data, Medical History, and Donor Data, Blood Draws for Control Group, Blood Draws for Experimental Group, Donor Blood Draws, Donor Information, Kidney Biopsy
Drug · Other · Procedure
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 70 Years
Enrollment
275 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2019
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 28, 2019 · Synced Oct 21, 2026, 5:10 AM EDT
Completed Phase 4 Interventional Results available

Effect of Sitagliptin and an ACE Inhibitor on Blood Pressure in Metabolic Syndrome

NCT00666848
View directory record Official record
Conditions
Metabolic Syndrome, Hypertension
Interventions
Placebo, Enalapril 5mg, Enalapril 10mg, Sitagliptin
Drug
Lead sponsor
Vanderbilt University
Other
Eligibility
18 Years to 70 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated May 11, 2012 · Synced Oct 21, 2026, 5:10 AM EDT
Completed Phase 4 Interventional Results available

An Examination of the Blood Pressure Lowering Ability and Safety of Olmesartan Medoxomil in Elderly Patients With Hypertension

NCT00412932
View directory record Official record
Conditions
Hypertension
Interventions
Olmesartan medoxomil, Olmesartan medoxomil/hydrochlorothiazide
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
65 Years and older
Enrollment
178 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
29
States / cities
Birmingham, Alabama • Mesa, Arizona • Long Beach, California + 26 more
Source: ClinicalTrials.gov public record
Updated Sep 22, 2009 · Synced Oct 21, 2026, 5:10 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Angioedema Biomarker Research Study

NCT06210698
View directory record Official record
Conditions
Angioedema, Angioedemas, Hereditary, Urticaria, Mastocytosis, ACE Inhibitor-Induced Angioedema, C1 Inhibitor Deficiency, Systemic Mastocytoses, Indolent Systemic Mastocytosis
Interventions
Venipuncture
Diagnostic Test
Lead sponsor
Foundation For Rare Disease Research
Other
Eligibility
12 Years to 75 Years
Enrollment
600 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2027
U.S. locations
1
States / cities
Wheaton, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 24, 2026 · Synced Oct 21, 2026, 5:10 AM EDT
Terminated Not applicable Interventional Results available

ACE-Inhibitor Effects on Total Hip and Knee Arthroplasty Patients

NCT01867047
View directory record Official record
Conditions
Adverse Effects of Angiotensin-converting-enzyme Inhibitors, Hypotension
Interventions
ACE-I Cessation group, ACE-I Continuation group
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 28, 2017 · Synced Oct 21, 2026, 5:10 AM EDT
Terminated Phase 4 Interventional Results available

Vascular Benefits of Adding CarvedilolCR to Type2 Diabetic Patients on ACEI.

NCT00430040
View directory record Official record
Conditions
Diabetes Mellitus, Type 2, Hypertension
Interventions
Carvedilol Controlled Release (CR), lisinopril
Drug
Lead sponsor
University at Buffalo
Other
Eligibility
18 Years to 70 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Apr 16, 2024 · Synced Oct 21, 2026, 5:10 AM EDT
Not listed Phase 2 Interventional Accepts healthy volunteers

Evaluation of Ecallantide for the Acute Treatment of Angiotensin Converting Enzyme Inhibitor Induced Angioedema

NCT01036659
View directory record Official record
Conditions
Angioedema
Interventions
ecallantide - Kallikrein inhibitor that blocks the production of bradykinin
Drug
Lead sponsor
Bernstein, Jonathan A., M.D.
Individual
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2013
U.S. locations
3
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 9, 2012 · Synced Oct 21, 2026, 5:10 AM EDT
Completed Not applicable Interventional

OPTImizing Precision of Hypertension Care to Maximize Blood Pressure Control Pilot (OPTI-BP Pilot)

NCT02814552
View directory record Official record
Conditions
High Blood Pressure
Interventions
HTN PRA App, Blood Sample
Other
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 65 Years
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
3
States / cities
Macclenny, Florida • Old Town, Florida • Tallahassee, Florida
Source: ClinicalTrials.gov public record
Updated Oct 25, 2018 · Synced Oct 21, 2026, 5:10 AM EDT
Completed Phase 4 Interventional Results available

Angiotensin II in General Anesthesia

NCT03733145
View directory record Official record
Conditions
Hypertension
Interventions
Angiotensin II
Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
40 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 24, 2025 · Synced Oct 21, 2026, 5:10 AM EDT
Terminated Not applicable Interventional

ACEI/ARB Study in Ambulatory and Day of Surgery Admission Patients

NCT03121092
View directory record Official record
Conditions
Hypertension, Hypotension
Interventions
ACEI or ARB
Drug
Lead sponsor
State University of New York - Downstate Medical Center
Other
Eligibility
18 Years and older
Enrollment
188 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
1
States / cities
Brooklyn, New York
Source: ClinicalTrials.gov public record
Updated Apr 19, 2017 · Synced Oct 21, 2026, 5:10 AM EDT
Completed No phase listed Observational

Preserving Kidney Function in Children With Chronic Kidney Disease

NCT05169411
View directory record Official record
Conditions
Chronic Kidney Disease Stage 2, Chronic Kidney Disease Stage 3, Pediatric Kidney Disease
Interventions
Blood pressure, Urine protein
Diagnostic Test
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
1 Year to 17 Years
Enrollment
20,240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 16, 2024 · Synced Oct 21, 2026, 5:10 AM EDT
Completed Phase 2 Interventional Results available

Safety, Tolerability and Efficacy of Nidufexor in Patients With Diabetic Nephropathy

NCT03804879
View directory record Official record
Conditions
Diabetic Nephropathy
Interventions
Nidufexor, Placebo, Standard of Care (SoC)
Drug · Other
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
83 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
5
States / cities
Miami Lakes, Florida • Albany, New York • Norman, Oklahoma + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 10, 2022 · Synced Oct 21, 2026, 5:10 AM EDT